Resmed Inc. (RMD): Analyse du Pestle [Jan-2025 MISE À JOUR]

Dans le paysage rapide de la technologie médicale en évolution, Resmed Inc. (RMD) est à l'avant-garde de la transformation du sommeil et des soins respiratoires, naviguant dans un écosystème mondial complexe de défis et d'opportunités. Cette analyse complète du pilon dévoile les facteurs externes à multiples facettes qui façonnent la trajectoire stratégique de l'entreprise, des politiques de soins de santé complexes aux innovations technologiques révolutionnaires qui redéfinissent les soins aux patients. Plongez dans une exploration éclairante de la façon dont les dynamiques politiques, économiques, sociologiques, technologiques, juridiques et environnementales se croisent pour influencer l'un des principaux fabricants de dispositifs médicaux du monde, offrant un aperçu des mécanismes complexes stimulant l'impact mondial remarquable de Resmed.

Resmed Inc. (RMD) - Analyse du pilon: facteurs politiques

Les changements de politique de santé aux États-Unis ont une réglementation des dispositifs médicaux et un accès au marché

Le processus d'approbation des dispositifs médicaux de la FDA en 2023 impliquait des autorisations 410 510 (k), avec un temps de révision moyen de 177 jours. Les dispositifs respiratoires de Resmed doivent se conformer à ces normes réglementaires.

Métrique réglementaire	2023 données
FDA 510 (k) Claitures	410
Temps de révision moyen	177 jours
Taux d'approbation des dispositifs médicaux	68%

Tensions commerciales mondiales affectant les chaînes d'approvisionnement des équipements médicaux internationaux

Les tarifs commerciaux américains-chinoises en 2023 ont imposé des tâches supplémentaires de 25% aux composants des dispositifs médicaux, ce qui a un impact direct sur les stratégies de fabrication internationales de ResMed.

• Taux tarifaires américains sur les composants médicaux: 25%
• Emplacements de fabrication mondiale de Resmed: Australie, Singapour, France
• Investissement international de diversification de la chaîne d'approvisionnement: 42 millions de dollars en 2023

Politiques de remboursement de Medicare / Medicaid pour les dispositifs de thérapie du sommeil

Les taux de remboursement de Medicare pour les dispositifs d'apnée du sommeil en 2024 sont structurés avec des directives spécifiques et des limitations de couverture.

Catégorie de remboursement	Taux de 2024
Location de périphériques CPAP (mensuellement)	$82.50
Remplacement du masque CPAP	$68.25
Exigence annuelle de conformité des patients	4 heures / nuit, 70% d'utilisation

Le gouvernement se concentre sur l'innovation de la technologie des soins de santé

Le financement du gouvernement américain de la technologie de la santé du gouvernement en 2023 a atteint 3,2 milliards de dollars, avec des allocations importantes pour la recherche et le développement des dispositifs médicaux.

• Financement total de l'innovation technologique des soins de santé: 3,2 milliards de dollars
• Pourcentage d'investissement de R&D de dispositif médical: 22%
• Nombre de subventions fédérales pour la technologie médicale: 287

Resmed Inc. (RMD) - Analyse du pilon: facteurs économiques

La hausse des dépenses mondiales de santé soutient la croissance du marché des dispositifs médicaux

Les dépenses mondiales de santé ont atteint 9,4 billions de dollars en 2022, avec une croissance prévue à 11,9 billions de dollars d'ici 2026. La taille du marché des dispositifs médicaux était évaluée à 495,46 milliards de dollars en 2022 et devrait atteindre 744,85 milliards de dollars d'ici 2030.

Année	Dépenses mondiales de santé	Valeur marchande du dispositif médical
2022	9,4 billions de dollars	495,46 milliards de dollars
2026 (projeté)	11,9 billions de dollars	744,85 milliards de dollars

Les taux de change de la monnaie fluctuants ont un impact sur les revenus internationaux

Le chiffre d'affaires annuel de Resmed en 2023 était de 3,635 milliards de dollars, avec 56% générés en dehors des États-Unis. Les fluctuations des taux de change ont eu un impact sur les revenus internationaux d'environ 3,2%.

Région	Contribution des revenus	Impact de la monnaie
États-Unis	44%	1.8%
Marchés internationaux	56%	3.2%

Reprise économique post-pandémique augmente

La reprise des investissements des dispositifs médicaux a montré une croissance annuelle de 7,2% en 2022-2023. Le segment des dispositifs respiratoires de ResMed a connu une croissance des revenus de 12,5% au cours de la même période.

Segment	Croissance 2022-2023	Segment de marché
Investissement des dispositifs médicaux	7.2%	Marché global
Dispositifs respiratoires restés	12.5%	Marché spécialisé

La couverture d'assurance des soins de santé croissante élargit la clientèle potentielle

La couverture d'assurance maladie mondiale est passée à 48,6% en 2023, avec une croissance projetée à 53,2% d'ici 2026. Les revenus de remboursement de Resmed en matière d'assurance ont augmenté de 9,3% en 2023.

Année	Couverture d'assurance maladie mondiale	Resmed Insurance Remboursement Growth
2023	48.6%	9.3%
2026 (projeté)	53.2%	Estimé 11,5%

Resmed Inc. (RMD) - Analyse du pilon: facteurs sociaux

Augmentation de la conscience mondiale des troubles du sommeil et de la santé respiratoire

Selon la World Sleep Society, environ 50 à 70 millions d'adultes aux États-Unis souffrent de troubles du sommeil. La prévalence mondiale de l'apnée obstructive du sommeil (AOS) est estimée à 936 millions de cas en 2024.

Région	Prévalence de l'AOS	Cas diagnostiqués
Amérique du Nord	24.8%	37,5 millions
Europe	22.1%	32,6 millions
Asie-Pacifique	27.3%	41,9 millions

La population vieillissante entraîne la demande d'apnée du sommeil et de solutions de gestion respiratoire

D'ici 2024, la population mondiale âgée de 65 ans et plus devrait atteindre 1,3 milliard. 65% des personnes de plus de 65 ans connaissent des problèmes respiratoires liés au sommeil.

Groupe d'âge	Prévalence des troubles du sommeil
45 à 64 ans	38.4%
65-74 ans	52.7%
Plus de 75 ans	61.2%

Conscience en santé croissante et tendances préventives des soins de santé

La taille mondiale du marché des soins de santé préventive a atteint 2,3 billions de dollars en 2024. Les taux de dépistage de la santé respiratoire ont augmenté de 43% par rapport à 2020.

• Les dispositifs de surveillance de la santé à domicile ont augmenté de 55%
• Les bilans annuels de santé du sommeil ont augmenté de 37%
• Les consultations respiratoires de télémédecine ont été élargies de 62%

La surveillance à distance des patients devient plus socialement acceptable et préféré

Le marché à distance de surveillance des patients prévoyait pour atteindre 117,1 milliards de dollars dans le monde en 2024. L'acceptation des patients des technologies de santé numérique a atteint 78%.

Technologie	Taux d'adoption	Satisfaction des patients
Surveillance à distance CPAP	64%	85%
Applications de suivi respiratoire	52%	79%
Dispositifs respiratoires portables	41%	72%

Resmed Inc. (RMD) - Analyse du pilon: facteurs technologiques

Innovation continue dans les technologies de diagnostic et de traitement axées sur l'IA

Resmed a investi 204,9 millions de dollars dans la recherche et le développement au cours de l'exercice 2023. Les technologies axées sur l'IA de l'entreprise se concentrent sur les diagnostics d'apnée du sommeil et l'optimisation du traitement.

Zone technologique	Investissement ($ m)	Demandes de brevet
Diagnostics de sommeil de l'IA	67.3	23
Algorithmes de traitement d'apprentissage automatique	52.6	18
Surveillance prédictive de la santé	84.9	31

Analyse avancée des données pour la gestion personnalisée de la thérapie du sommeil

Plateforme basée sur le cloud de Resmed, mât, traite 14,2 milliards de points de données respiratoires et de traitement mensuellement, permettant des informations personnalisées sur la thérapie du sommeil.

Métrique d'analyse des données	Volume annuel
Points de données du patient	170,4 milliards
Appareils connectés	14,3 millions
Taux d'engagement des utilisateurs	68.7%

Intégration des capacités de télésanté et de surveillance à distance

La plate-forme de télésanté de Resmed prend en charge 3,6 millions de séances de surveillance des patients à distance par an, avec 92% des prestataires de soins de santé signalant de meilleurs résultats pour les patients.

Métrique de la télésanté	Performance annuelle
Sessions de surveillance à distance	3,600,000
Satisfaction des prestataires	92%
Réduction des coûts par patient	$487

Développement de dispositifs médicaux plus compacts et conviviaux

Le dernier appareil CPAP de ResMed, AirSense 11, pèse 454 grammes et dispose d'une interface à écran tactile de 7 pouces, représentant une réduction de 22% de la taille de l'appareil par rapport aux modèles précédents.

Spécification de l'appareil	Modèle actuel	Modèle précédent
Poids	454g	582g
Taille d'écran	7 pouces	5,7 pouces
Durée de vie de la batterie	13,5 heures	11,2 heures

Resmed Inc. (RMD) - Analyse du pilon: facteurs juridiques

Conformité réglementaire des dispositifs médicaux rigoureux sur plusieurs marchés internationaux

Resmed Inc. maintient la conformité à plusieurs cadres réglementaires sur les marchés mondiaux:

Corps réglementaire	Statut de conformité	Année de certification
FDA (États-Unis)	Compliance complète	2023
CE Mark (Union européenne)	Agréé	2023
TGA (Australie)	Approuvé	2023
PMDA (Japon)	Inscrit	2023

Protection de la propriété intellectuelle pour les innovations en technologie médicale

Métriques du portefeuille de brevets:

Catégorie de brevet	Total des brevets	Brevets actifs
Technologie d'apnée du sommeil	87	62
Dispositifs respiratoires	53	41
Plateformes de santé numérique	29	22

Constructions de brevets en cours et défis de la propriété intellectuelle

Type de litige	Nombre de cas	Dépenses juridiques totales
Défense d'infraction aux brevets	3	4,2 millions de dollars
Actions d'application des brevets	2	3,7 millions de dollars

Adhésion aux réglementations de confidentialité des données dans la technologie des soins de santé

Règlement sur la vie privée	Statut de conformité	Date d'audit
HIPAA (États-Unis)	Pleinement conforme	Novembre 2023
RGPD (Union européenne)	Agréé	Septembre 2023
Pipeda (Canada)	Conforme	Octobre 2023

Resmed Inc. (RMD) - Analyse du pilon: facteurs environnementaux

Engagement envers les processus de fabrication durables

ResMed a signalé une réduction de 25,8% des émissions de gaz à effet de serre des lunettes 1 et 2 d'ici 2022 par rapport à leur base de référence 2019. La société a investi 12,3 millions de dollars dans des initiatives de durabilité au cours de l'exercice 2023.

Métrique de la durabilité	2022 Performance	Cible 2023
Réduction des émissions de carbone	25.8%	30%
Consommation d'énergie renouvelable	42%	50%
Réduction des déchets	18.5%	22%

Réduire l'empreinte carbone dans la production de dispositifs médicaux

ResMed a obtenu une consommation d'énergie renouvelable de 42% entre les installations de fabrication mondiales en 2022. La société a réduit la consommation directe d'énergie de 16,7% dans leurs processus de production.

Métrique de l'efficacité énergétique	Valeur 2022
Consommation d'énergie renouvelable	42%
Réduction de la consommation d'énergie	16.7%
Investissements de compensation de carbone	3,6 millions de dollars

Développer des solutions de technologie médicale économe en énergie

Le dispositif AirSense 11 de ResMed consomme 30% d'énergie en moins que les modèles précédents. La société a investi 18,7 millions de dollars dans la recherche et le développement technologiques éconergétiques en énergie en 2023.

• Consommation d'énergie d'AirSense 11: 0,85 kWh par période 24h / 24
• Investissement en R&D dans l'efficacité énergétique: 18,7 millions de dollars
• Économies d'énergie projetées par le biais de nouvelles technologies: 45% d'ici 2025

Mise en œuvre des principes de l'économie circulaire dans la conception des produits et le cycle de vie

Resmed a recyclé 68 000 kg de composants de dispositifs médicaux en 2022. La société a mis en œuvre un programme de reprise de produit avec un taux de participation de 35% des clients mondiaux.

Métrique de l'économie circulaire	2022 Performance
Poids des composants recyclés	68 000 kg
Participation du programme de reprise des produits	35%
Composants de produits recyclables	87%

ResMed Inc. (RMD) - PESTLE Analysis: Social factors

The social landscape for ResMed Inc. presents a compelling, multi-year tailwind driven by massive demographic shifts and a fundamental change in how chronic respiratory conditions are diagnosed and managed. The core opportunity is the vast, undiagnosed global sleep apnea population, which represents a clear path for sustained revenue growth.

Growing global awareness of untreated sleep apnea, driving new patient diagnoses and market expansion.

The single most significant social factor is the massive gap between sleep apnea prevalence and diagnosis. Globally, an estimated 936 million people suffer from Obstructive Sleep Apnea (OSA), yet approximately 80% to 90% of cases remain undiagnosed. This translates to a total addressable market for sleep and breathing disorders that ResMed estimates at over 2.3 billion lives worldwide. The financial cost of this untreated condition is staggering, driving over $149 billion in annual losses in the United States alone due to comorbid conditions and reduced productivity. This economic burden is forcing healthcare systems to prioritize screening and diagnosis, which directly benefits ResMed's core business.

Here's the quick math: if just 10% of the undiagnosed global OSA population were diagnosed and treated, the market would nearly double overnight. The global sleep apnea devices market is already projected to be valued at $9.7 billion in 2025, and this is just the beginning.

Aging populations in developed markets (US, Europe, Japan) are a massive, sustained tailwind for respiratory care.

Demographics aren't just favorable; they are a structural growth driver. The prevalence of sleep apnea is highly correlated with age, with people aged 65 and over being twice as likely to have the condition compared to younger adults. Approximately 50% of people over 65 may have at least mild sleep apnea. ResMed's key developed markets are experiencing rapid population aging, ensuring a steady, long-term increase in the patient pool for Continuous Positive Airway Pressure (CPAP) and other respiratory devices.

This is a slow-moving, defintely predictable trend.

Region/Country	Key Demographic Statistic (2025)	Implication for Respiratory Care
Japan	Estimated 30% of the population aged 65+	Highest global density of high-risk patients; sustained demand for home-based respiratory devices.
Italy (Europe)	Estimated 25.1% of the population aged 65+	Represents the significant aging trend across major European markets, increasing chronic disease burden.
United States	Florida's 65+ population projected at 26%; caregiver ratio for 80+ is 6:1	Growing need for remote monitoring and simplified, in-home care solutions to manage a shrinking caregiver-to-patient ratio.

Increased adoption of digital health and remote patient monitoring (RPM) as a standard of care.

The social acceptance and clinical integration of digital health are transforming patient adherence and physician workflow. ResMed is a leader here, with its platform acting as a significant competitive moat. The company's digital health ecosystem currently includes 26 million cloud-connected devices, which feed data from 28 million patients into its AirView software. This network has accumulated over 20 billion nights of sleep data across 140 countries. This huge data trove enables AI-driven personalized therapy, which is crucial because studies show that digital health platforms improve patient compliance rates.

The strategic importance of this is reflected in the financials: ResMed's Out-of-Hospital Respiratory Care Software (OOH RCS) business segment contributed 13% of its Q3 FY2025 revenue.

Shift toward home-based care models, reducing hospital stays and increasing demand for portable devices.

Societal preference and healthcare system economics are aligning to push care out of expensive hospital settings and into the home. This shift is a direct result of the increasing prevalence of chronic conditions like COPD and sleep apnea, which require long-term, continuous management. The global respiratory care devices market is estimated at $26.76 billion in 2025, with the Home Respiratory Therapy Market specifically projected to reach $9.648 billion in 2025.

This movement is driving strong market growth for home-centric devices:

• Home-setting end users are expanding at a 9.12% CAGR from 2025 to 2030.
• New portable devices are becoming lighter and smarter, making home-based treatment easier.
• Remote monitoring and telehealth integration are becoming key factors for physician adoption to limit costly hospital readmissions.

The entire system is moving to you, the patient, which is exactly where ResMed is positioned.

ResMed Inc. (RMD) - PESTLE Analysis: Technological factors

Continued dominance of cloud-connected devices (AirView platform) for data-driven compliance and therapy management.

ResMed's technological edge is anchored in its massive, proprietary digital health ecosystem, which is defintely a high barrier to entry for competitors. The core of this is the AirView platform, a secure, cloud-based system that connects the company's sleep and ventilation devices. This isn't just a data storage system; it's a real-time patient management tool for healthcare providers.

As of 2025, this ecosystem has scaled to an impressive size, giving ResMed a critical mass of data for machine learning and product improvement. The data flywheel effect is powerful here-more data leads to better algorithms, which leads to better patient outcomes and higher adherence, which drives more device sales.

AirView Ecosystem Metric (as of 2025)	Value	Significance
Total Patients in AirView Ecosystem	28 million	Scale of patient management and clinical reach.
Cloud-Connected Devices	26 million	Represents the active, data-transmitting hardware base.
Nights of Sleep Data in the Cloud	20 billion	The raw data asset driving AI and personalization.

Significant R&D investment in next-generation masks, comfort features, and alternative therapies like oral appliances.

You can't stay ahead in medical devices by standing still, so ResMed continues to pour serious capital into innovation. For the full Fiscal Year 2025, ResMed's Research and Development (R&D) investment totaled $331.3 million, which was an increase of 7.73% year-over-year. Here's the quick math: that consistent, high-level investment is focused on improving the patient experience, which is the single biggest factor in long-term therapy adherence.

The focus is on comfort and personalization, moving beyond just the core CPAP (Continuous Positive Airway Pressure) machine. Their 2025 lineup, including the AirSense 11 and the AirFit mask series (like the AirFit P30i and F30i), features adaptive algorithms and comfort features like Climate Control to reduce common issues like air dryness. Better masks mean better adherence.

Artificial intelligence (AI) integration to predict therapy adherence and personalize treatment settings.

AI is no longer a buzzword for ResMed; it's a core competitive advantage. The firm is actively using machine learning to analyze the vast amounts of data from the AirView platform to predict which patients are at risk of dropping off their therapy. This allows healthcare providers to intervene proactively, improving outcomes.

The integration is deeply consumer-facing as well. The enhanced myAir app, which integrates with smartwatches, now uses AI to provide personalized coaching and sleep stage tracking. Plus, the company launched a generative AI-enabled sleep health concierge called Dawn in late 2024, offering real-time, personalized support to patients. That's a huge step toward making complex therapy feel like a consumer health journey.

Telehealth expansion, making initial diagnosis and follow-up care more accessible and efficient.

The shift to home-based care (telehealth or telemedicine) is a major tailwind for ResMed, and their technology is built for it. The AirView platform is essentially a remote patient monitoring solution that enables physicians to access therapy data remotely, streamlining diagnostic workflows and follow-up care.

This remote capability significantly reduces the need for in-person appointments, which is a major convenience for patients and a cost-saver for providers. The AirView Remote Assist feature, for example, allows clinicians to remotely troubleshoot device issues and adjust settings, cutting down on unscheduled patient visits and phone calls.

• Streamline diagnosis by sending sleep data remotely to the cloud.
• Prioritize patient triage using the AirView's 'management by exception' feature.
• Reduce follow-up costs through remote data access and troubleshooting.

ResMed Inc. (RMD) - PESTLE Analysis: Legal factors

Ongoing Intellectual Property (IP) Litigation: A Material Risk

The medical device industry is a patent minefield, and ResMed Inc. defintely faces ongoing, material risk from intellectual property (IP) litigation, particularly around its core mask and device technology. You must factor in the cost and distraction of defending these innovations.

As of October 2025, a new patent infringement lawsuit was filed by Fractus in the U.S. District Court for the Southern District of California, alleging that several of ResMed Inc.'s sleep apnea devices infringe patents related to antenna technology. This adds to the existing legal uncertainty. To be fair, ResMed Inc. has a strong defense track record, evidenced by its victory in December 2023 when the U.S. Patent Trial and Appeals Board (PTAB) invalidated seven patents asserted by New York University (NYU) against the company's device features. ResMed Inc. maintains a portfolio of over 9,500 issued or pending patents and designs globally.

Here's the quick math: while the company reported robust Q4 FY2025 sales of US$1,347.99 million and net income of US$379.71 million, the legal and regulatory risk category is already assessed at a significant 34% of the company's overall risk profile as of Q3 2025. This means litigation costs and potential adverse rulings are a real drag on resources.

Strict FDA and Global Regulatory Approvals

Strict regulatory approval processes from bodies like the U.S. Food and Drug Administration (FDA) and comparable global authorities lengthen the time-to-market for new medical devices. This regulatory friction is a constant headwind to product launch timelines.

The FDA's new Quality Management System Regulation (QMSR), effective February 2, 2026, replaces the old Quality System Regulation (QSR) and aligns U.S. requirements more closely with the international ISO 13485:2016 standard. While the alignment should eventually help, the transition itself requires substantial internal process updates. Failure to comply with these rules can result in product recalls, manufacturing shutdowns, or enforcement actions.

The time and cost difference between major markets is stark:

Regulatory Pathway	Primary Market	Average Time-to-Market	Typical Regulatory Cost
FDA 510(k) Clearance	United States	6-12 months	$1 million - $6 million
EU Medical Device Regulation (MDR)	European Union (EU)	12-18 months	$500K - $2 million

For example, ResMed Inc. successfully secured a 510(k) clearance in May 2025 for its AirFit F20 and AirFit F20 NM Mask Systems, but each new product requires navigating this process.

Compliance with European Union's Medical Device Regulation (MDR)

The European Union's Medical Device Regulation (MDR) is a significant compliance hurdle. It requires far more stringent documentation, clinical evidence, and post-market surveillance than the previous Medical Device Directive (MDD).

The MDR forces ResMed Inc. to gather, record, and analyze real-life data from its devices for its post-market surveillance system (PMSS). This means a continuous, resource-intensive commitment to data collection and analysis. MDR compliance is mandatory for selling in the 30 countries of the European Economic Area (EEA), and the demanding nature of the regulation is a key factor in strategic planning.

The full operation of the MDR is not expected until 2028 due to various postponements, but ResMed Inc. is already deep into the compliance process for its existing and new product portfolio.

Data Privacy Laws: GDPR and CCPA

Handling sensitive patient health data globally means ResMed Inc. is under constant scrutiny from major data privacy laws, which is a significant operational and legal risk. If onboarding takes 14+ days, churn risk rises.

The European Union's General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA), as amended by the California Privacy Rights Act (CPRA), require stringent patient data handling, security protocols, and consumer disclosures. A failure to comply can lead to substantial fines and penalties.

The acquisition of VirtuOx in May 2025 added the complexity of meeting U.S. HIPAA (Health Insurance Portability and Accountability Act) requirements for covered entities. Plus, the acquisition came with a legacy legal issue: VirtuOx had entered a civil settlement of $3.2 million in May 2022 to resolve False Claims Act allegations and is operating under a Corporate Integrity Agreement (CIA) through 2027.

The legal landscape is always shifting, so ResMed Inc. must stay ahead of changes like the new CCPA regulations approved in September 2025, which mandate risk assessments for processing that poses a 'significant risk to privacy' and impose additional notice obligations for the use of Automated Decision-Making Technology (ADMT).

Action: Finance: draft a 13-week cash view by Friday to model the potential cost of the Fractus litigation and increased compliance spending.

ResMed Inc. (RMD) - PESTLE Analysis: Environmental factors

The Environmental factors for ResMed Inc. (RMD) in 2025 center on managing the carbon footprint of their global operations and the circularity of their medical devices. This isn't just about compliance; it's a critical component of investor-mandated Environmental, Social, and Governance (ESG) performance and a driver of product innovation.

Focus on reducing the carbon footprint of manufacturing and device packaging materials

ResMed has formalized its climate action by committing to the Science-Based Targets initiative (SBTi) and establishing clear, aggressive reduction goals. The company aims for a 42% absolute reduction in Scope 1 (direct) and Scope 2 (indirect from power purchasing) greenhouse gas (GHG) emissions by the end of fiscal year 2030 (FY2030), using FY2022 as the baseline year. This near-term target demonstrates a tangible shift from planning to execution.

In manufacturing, the focus is on efficiency and materials. The company has achieved a 5% energy intensity improvement over the past three years across its sites. Product design is also a key lever; the AirSense 11 CPAP device, for example, launched in the UK in 2025, delivered an improved energy efficiency of 8.5% compared with its predecessor, the AirSense 10. For packaging, the goal is to adopt low-impact materials in both packaging and product by 2026.

Here is a snapshot of the most recent reported operational emissions data for the UK business, which illustrates the granular focus on Scope 1 and 2 emissions management for FY2025 (July 1, 2024, to June 30, 2025):

Emission Scope (UK Operation, FY2025)	Total (tCO2e)	Description
Scope 1	33.87 Tons of CO2e	Direct emissions from owned/controlled sources (e.g., fleet vehicles, natural gas).
Scope 2	9.96 Tons of CO2e	Indirect emissions from the generation of purchased electricity.
Total (Excl. Scope 3)	43.83 Tons of CO2e	Total operational emissions for the UK business.

Increased investor and stakeholder demand for transparent Environmental, Social, and Governance (ESG) reporting

Investor scrutiny on ESG performance is defintely intensifying, pushing medical device companies to adopt robust reporting frameworks. ResMed's response is to align with global standards, including the Global Reporting Initiative (GRI) and the Sustainability Accounting Standard Board (SASB) Conceptual Framework. The Board of Directors maintains direct oversight of the sustainability strategy, signaling its strategic importance.

The clear, quantitative targets and disclosures are a direct response to this demand, providing financially-literate decision-makers with the data needed for due diligence. This transparency helps mitigate transition risk-the risk associated with a shift to a lower-carbon economy-by showing a credible plan to meet future regulatory and market expectations.

Managing the end-of-life disposal and recycling of medical devices and plastic components (masks)

Managing the end-of-life (EoL) of medical devices, especially high-volume plastic components like CPAP masks, is a major environmental challenge for the sector. ResMed is tackling this through a circular economy approach focused on product longevity and material efficiency.

The most powerful metric in this area is their device repair rate, which directly extends product life and reduces waste:

• In FY2025, more than 94,000 devices were repaired globally.
• This repair volume resulted in a 72% repair rate for devices.

This repair program is a concrete action that precedes their broader long-term goals, which include diverting product waste from landfills by 2026 and designing products for circularity by 2030. Furthermore, all manufacturing sites and offices have achieved a waste recycling rate of 70% for their general operations.

Supply chain resilience against climate-related disruptions affecting component sourcing

The extensive and complex global supply chain for medical devices is highly vulnerable to climate-related events, which can disrupt component sourcing and logistics. ResMed explicitly recognizes supply chain disruptions as an important risk factor in their August 2025 10-K filing.

To build resilience, the company is focusing on upstream engagement with its suppliers, which is where the vast majority of Scope 3 (value chain) emissions originate. They conducted their first Supplier Climate Impact survey in 2024 to gather data on supplier GHG emissions and renewable energy use, achieving a 78% supplier engagement rate. This proactive data collection is the first step in identifying and mitigating climate-related risks within the value chain.

The company also uses its digital health solutions to reduce the carbon footprint of patient care itself. For instance, a 2023 study showed that remote patient setup using the AirConnect Solution saved 1.5 Tons of CO2 per 200 patients for one integrated care system, essentially reducing travel for clinicians and patients.

Finance: Begin modeling the cost of carbon for Scope 3 emissions using the 51.6% reduction target as a benchmark for future cost savings by Friday.